Our mission, editorial standards, and how we keep information accurate.
GLP-1 Guide was built with one goal: give patients clear, accurate, and useful information about GLP-1 weight loss and diabetes medications — without medical jargon, without pharmaceutical bias, and without making it harder than it needs to be.
Millions of Americans are starting GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound. Most of them have the same questions: What's the difference between these drugs? How do I dose it? How much will it cost? What can I eat? What side effects should I watch for?
We built the tools and content we wished existed when we started researching these medications ourselves.
All factual claims are sourced from FDA prescribing information, peer-reviewed clinical trials (STEP, SUSTAIN, SURPASS, SURMOUNT programs), NIH publications, or manufacturer-published data. We do not publish anecdotal claims without clearly labeling them as such.
GLP-1 Guide provides general health information only. We do not provide medical advice, diagnosis, or treatment recommendations. All content includes a reminder to consult a qualified healthcare provider. Our tools (dosing calculator, cost calculator) are for informational purposes — final decisions should always be made with your doctor.
The GLP-1 space moves fast. Drug pricing changes, FDA approvals evolve, new trial data publishes regularly. We review all core content pages at minimum quarterly, and update drug-specific pages whenever significant new information is available. Each page displays its last review date.
This site is monetized through Google AdSense display advertising and affiliate links to telehealth services. We clearly label advertisements. Affiliate relationships do not influence our editorial content — we do not give preferential coverage to paying partners. Our drug comparisons and rankings are based solely on clinical data.
We recognize that health content falls under Google's "Your Money or Your Life" (YMYL) category and take that responsibility seriously. We apply Google's E-E-A-T framework (Experience, Expertise, Authoritativeness, Trustworthiness) to all content production.
Official drug approval records, prescribing information (drug labels), safety communications, shortage database.
STEP 1–4 (Wegovy/Ozempic), SUSTAIN 1–6 (Ozempic cardiovascular), SURPASS 1–5 (Mounjaro), SURMOUNT 1–5 (Zepbound), SELECT (Wegovy heart), SURMOUNT-5 (head-to-head).
National Institutes of Health publications, New England Journal of Medicine, The Lancet, JAMA, Diabetes Care.
Novo Nordisk and Eli Lilly prescribing information, patient guides, pricing information, and savings program details.
The information on GLP-1 Guide is intended for general informational purposes only and should not be interpreted as medical advice, diagnosis, or treatment recommendations. Always seek the advice of your physician, pharmacist, or other qualified healthcare provider with any questions you may have regarding a medical condition or medication.
Never disregard professional medical advice or delay in seeking it because of information you have read on this website. If you think you may have a medical emergency, call your doctor or emergency services immediately.
Drug pricing, availability, insurance coverage, and clinical guidelines change frequently. While we make every effort to keep information current, we cannot guarantee that all information reflects the most recent changes. Always verify critical information with your healthcare provider and insurance company.
Found an error? Have a suggestion? We take accuracy seriously and want to hear from you.
We aim to respond to editorial correction requests within 48 hours. Verified errors will be corrected and noted in the content.